Abstract
A Phase II trial of TCN-P was conducted in metastatic or recurrent squamous cell carcinoma of the cervix using a 5-day continuous infusion schedule. The starting dose was 35 mg/m2 x 5 days and courses were repeated every 6 weeks. Among 21 evaluable patients, 2 responses were observed. One patient had a complete response for 19+ months. Another patient had a partial response for 5+ months, but developed symptomatic hypocalcemia, requiring discontinuation of the drug. Using this dose and schedule TCN-P appears to have limited activity in metastatic or recurrent squamous cell cancer of the cervix.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 506-508 |
| Number of pages | 3 |
| Journal | American Journal of Clinical Oncology: Cancer Clinical Trials |
| Volume | 16 |
| Issue number | 6 |
| DOIs | |
| State | Published - Jan 1 1993 |
| Externally published | Yes |
ASJC Scopus subject areas
- Oncology
- Cancer Research
Fingerprint Dive into the research topics of 'A Phase II trial of tricyclic nucleoside phosphate in patients with advanced squamous cell carcinoma of the cervix: A Gynecologic Oncology Group study'. Together they form a unique fingerprint.
Cite this
Feun, L. G., Blessing, J. A., Barrett, R. J., & Hanjani, P. (1993). A Phase II trial of tricyclic nucleoside phosphate in patients with advanced squamous cell carcinoma of the cervix: A Gynecologic Oncology Group study. American Journal of Clinical Oncology: Cancer Clinical Trials, 16(6), 506-508. https://doi.org/10.1097/00000421-199312000-00010